EGFR and non-small cell lung carcinoma: Approximately 10% of NSCLC patients manifest mutations of epidermal growth factor receptor (EGFR), resulting in hyperactivation of downstream oncogenic pathways related to cell proliferation and survival [1]; hence pointing out a therapeutic opportunity through the pharmacological blockade of EGFR.